½÷¥ß¬ã¨s³¡§Ö°T
¬d¬Ý©õ¤é¬ã¨s³¡§Ö°T Âà±Hµ¹ªB¤Í §K¶O­q¾\ ·N¨£´£¨Ñ English Version
Phillip Home   6¤ë14¤é (¬P´Á¤­)

 

µÏ¦t¥ú¾Ç¬ì§Þ(2382)
¸Ñºc¡G
µÏ¦t¥ú¾Ç(2382)¥D­n±q¨Æ³]­p¡B¬ã¨s»P¶}µo¡B¥Í²£¤Î¾P°â¥ú¾Ç¤Î¥ú¾Ç¬ÛÃö²£«~¡A¸Óµ¥²£«~¥]¬A¥ú¾Ç¹s¥ó¡]¨Ò¦p¨®¸üÃèÀY¡B¨®¸ü¿E¥ú¹p¹F¥ú¾Ç³¡¥ó¡BVRªÅ¶¡©w¦ìÃèÀY¡B¤â¾÷ÃèÀY¡B¬Á¼þ²y­±©M«D²y­±Ãè¤ù¤Î¨ä¥L¥ú¾Ç¹s³¡¥ó¡^¡B¥ú¹q²£«~¡]¨Ò¦p¨®¸ü¼Ò²Õ¡BVRµøı¼Ò²Õ¡B¤â¾÷Äá¹³¼Ò²Õ¡B¾÷¾¹¤Hµøı¼Ò¶ô¤Î¨ä¥L¥ú¹q¼Ò²Õ¡^¤Î¥ú¾Ç»ö¾¹¡]¨Ò¦p´¼¯àÀË´ú³]³Æ¤ÎÅã·LÃè¡^¡C¶°¹Î±Mª`©óµ²¦X¥ú¾Ç¡B¹q¤l¡Bºâªk¤Î¾÷±ñ§Þ³Nªº¥ú¹q¬ÛÃö²£«~ªºÀ³¥Î»â°ì¡R¦p¨T¨®¡BVR/AR¡B¾÷¾¹¤H¤Î¤â¾÷¡C¦b¨®¸üÃèÀY¤è­±¡A¨®¸üÄá¹³ÀY¬°©Ò¦³¨T¨®´Â´¼¯à¤Æµo®iªºÃöÁä°t¸m¡A¤×¨ä¬O°ª¯Å»²§U¾r¾p¨t²Î¡]ADAS¡^¨®¸üÄá¹³ÀYªº¦¨ªø³Ì¬°¨³³t¡C©ó2023¦~¡A¶°¹Î¨®¸üÃèÀYªº¥X³f¶q¸û2022¦~¼Wªø¬ù15.1%¦Ü¬ù90,812,000¥ó¡A¥þ²y¥«¦û²v¤´©~­º¦ì¡A¨Ã¶i¤@¨B©Ô¤j¤F»P¥þ²y²Ä¤G¦ìªº®t¶Z¡C¦b¨®¸ü¥ú¾Ç·s¿³»â°ì¤è­±¡A¶°¹Î«ùÄò¦b¿E¥ú¹p¹F¡B©ïÀYÅã¥Ü¡]HUD¡^¤Î´¼¯à¨®¿O»â°ì¤¤«õ±¸¥«³õ¾÷¹J¡A¥[±j²£«~¥¬§½©M±M§Q¥¬§½¡A´M¨D§Þ³N¼h­±ªº®t²§¤Æ¬ð¯}¡C¦b®ø¶O¯Å·s¿³¥ú¾Ç¤è­±¡A¶°¹Î¶i¤@¨B¥[²`»P¥þ²y¦UVR¦W¥D¨¤«È¤áªº¾Ô²¤¦X§@¡A¶¶§Q¹F¦¨¤FÃöÁ䶵¥Øªº¶q²£¡C¦P®É¡A¶°¹Î¦bVRªñ²´Åã¥Ü¬ÛÃö²£«~©M·Pª¾»P¥æ¤¬ÃþÃèÀY¿n·¥§ë¤J¬ãµo¡B¥¬§½ÃöÁä§Þ³N»P¤uÃÀ¡A¦¨¬°¥þ²yª¾¦W«È¤áªº­º¿ï¨ÑÀ³°Ó¡C¦¹¥~¡A¶°¹Î¦bAR¥úªi¾É¡B¥ú¾÷¤Î¥ú¤ÞÀº¤è­±«ùÄò¥[±j¬ãµo¤O«×¨Ã´£¤É³W¼Ò¤Æªº²£«~»s³y¯à¤O¡A¬°«È¤á´£¨Ñ¥]¬AAR²£«~¥ú¾Ç§Þ³Nºî¦X¸Ñ¨M¤è®×¦b¤ºªº¦hºØ²£«~¿ï¾Ü¡C(µ§ªÌ¨S¦³«ù¦³¤W­zªÑ²¼)
µ¦²¤¡G
¶R¤J»ù$46.00¡A¥Ø¼Ð»ù$50.00¡A¤î»k»ù$44.00
 

«H¸q¯à·½(3868)
¸Ñºc¡G
ºI¦Ü2023¦~12¤ë©³¤î¦~«×¡A«H¸q¯à·½¡]03868¡^ºî¦X¦¬¯q¸û2022¦~¤W¤É8.7%¦Ü25.17»õ¤¸¡]´ä¤¸¡D¤U¦P¡^¡CªÑªFÀ³¦û¦~¤º·¸§Q·L¼W2.2%¦Ü9.93»õ¤¸¡C¤½¥q¾Ö¦³¤Î¹BÀ窺¤j«¬¤Ó¶§¯àµo¹q³õ¶µ¥Ø¥Í²£ªº¹q¤O¸û2022¦~¼Wªø10.9%¡C¥Ñ©ó¦h´¹Öº»ù®æ¦Û2022¦~©³¶}©l¤U¶^¡A¥ú¥ñ²Õ¥ó»ù®æ¤Î¤Ó¶§¯àµo¹q³õ¶µ¥Øªº¦w¸Ë¦¨¥»¥ç©ó¦~¤º«ùÄò¤U­°¡C´Á¤º¡A¤½¥q¾Ö¦³¤Î¹BÀ窺¤j«¬¤Ó¶§¯àµo¹q³õ¶µ¥ØªºÁ`®Ö­ã®e¶q¬°3,650.5¥ü¥Ë¡A¨ä¤¤1,724¥ü¥ËÄݤWºô¹q»ù¬Fµ¦¤Î1,926.5¥ü¥ËÄÝ¥­»ù¤Wºô¬Fµ¦¡CÀHµÛ2023¦~¥[¤J¥­»ù¤Wºô¬Fµ¦¤Uªº¤Ó¶§¯àµo¹q³õ¶µ¥Ø¼W¥[¡A¤½¥qªº¸gÀç²{ª÷¬y¤w³v¨B§ïµ½¡C¤½¥q±NÄ~ÄòÂ×´I¨ä¤Ó¶§¯àµo¹q³õ²Õ¦X¡A¥[¤W¥À¤½¥q«H¸q¥ú¯à©ó2023¦~·s¼W¶W¹L1¦N¥Ëªº¤Ó¶§¯àµo¹q³õ¶µ¥Ø¡A¦]¦¹¾Ö¦³¥R¨¬ªºÀx³Æ¶µ¥Ø¥i¨Ñ¤½¥q¥¼¨Ó¦¬ÁÊ¡A®Æ¤½¥q¥iÄ~ÄòÂX¤j¨ä·~°È³W¼Ò¤Î¸ê²£²Õ¦X¡A¥H´£°ª¬Õ§Q¯à¤O¡C
µ¦²¤¡G
¶R¤J»ù$1.15¡A¥Ø¼Ð»ù$1.27¡A¤î»k»ù$1.08

ùÚ¦w°ê»Ú (1044.HK) - FY2023·~°È¤´¿ý±oí°·¼Wªø¡B°ªºÝ°ª¤ò§Q²£«~«ùÄò¼Wªø
ùÚ¦w°ê»Ú³Ð¥ß©ó1985¦~¡A¬O¥Ø«e°ê¤º³Ì¤jªº¥Í¬¡¥Î¯È©M°ü¥®½Ã¥Í¥Î«~»s³y°Ó¡AºX¤U¾Ö¦³¦wº¸¼Ö¡B¤ß¬Û¦L¡B¤C«×ªÅ¶¡¡B¦w¨à¼Ö¥|ªT¤¤°ê¹£¦W°Ó¼Ð¡A½Ã¥Í¤y¡B¯È§¿¿Ç¡B¥Í¬¡¥Î¯È¤T¤j¥D¾É²£«~¦b°ê¤º¥«¦û²v¦W¦C«e­T¡C......§ó¦h

2024¦~²Ä¤@©u¡G´¼¯à¤â¾÷¥«³õªº°ª¶¥¤ÆÁͶÕ

ÀHµÛ2024¦~²Ä¤@©uªºµ²§ô¡A¥þ²y´¼¯à¤â¾÷¥«³õ¦A¦¸ÃÒ©ú¤F¨ä«ùÄòªº¦¨ªø°Ê¯à©M§Þ³Nºt¶iªº§Ö³t¨B¥ï¡C®Ú¾ÚCounterpoint Researchªº¼Æ¾Ú¡A¥þ²y´¼¯à¤â¾÷¥X³f¶q¦~¼W6%¡A¦ÓÁ`¦¬¤J§ó¬O¦~¼W7%¡A¹F¨ì­º©u¾ú¥v·s°ª¡C³o¶µ¦¨ÁZªº¨ú±o¡A¥D­n±o¯q©ó·s¿³¥«³õªº±j«l»Ý¨D¥H¤Î°ªºÝ³]³......§ó¦h


  • °ê°È°|¤é«eµo¥¬¡m¤½¥­Ävª§¼f¬d±ø¨Ò¡n³W©w¡A°_¯ó³æ¦ì°_¯óªº¬Fµ¦±¹¬I¡A¤£±o§t¦³­­¨î©ÎªÌÅܬۭ­¨î¥«³õ­ã¤J©M°h¥X¡A­­¨î°Ó«~¡B­n¯À¦Û¥Ñ¬y°Ê¡A¼vÅT¥Í²£¸gÀ禨¥»µ¥¤º®e¡C±ø¨Ò­n¨D¡A°_¯óªº¬Fµ¦±¹¬I¤£±o¹ï¥«³õ­ã¤J­t­±²M³æ¥H¥~ªº¦æ·~¡B»â°ì¡B·~°Èµ¥¹Hªk³]¸m¼f§åµ{§Ç¡A¤£±o¹Hªk³]¸m©ÎªÌ±Â¤©¯S³\¸gÀçÅv¡A¤£±o³]¸m¤£¦X²z©ÎªÌª[µø©Êªº­ã¤J¡B°h¥X±ø¥ó¡C
  • ¬ü°ê³Ò¤u³¡¤½¥¬¡AºI¦Ü6¤ë8¤é¤î·í©P¡A­º¦¸¥Ó½Ð¥¢·~±ÏÀÙ¤H¼Æ24.2¸U¤H¡A«ö©P¼W¥[1.3¸U¤H¡A¥«³õ¹w´Á¬°22.5¸U¤H¡F«e­È­×­q¬°22.9¸U¤H¡C¬ü°ê¤W©P­º¦¸¥Ó»â¥¢·~±ÏÀÙ¤H¼Æ4©P§¡­È¬°22.7¸U¤H¡A«ö©P¼W¥[4750¤H¡CºI¦Ü6¤ë1¤é¤î·í©P¡A¬ü°êÄò»â¥¢·~±ÏÀÙ¤H¼Æ182¸U¤H¡A«ö©P¼W¥[3¸U¤H¡A¥«³õ¹w´Á¬°179.5¸U¤H¡C
  • °ê»Ú°]¸g
    • ¬ü°ê°]ªø­C­Ûªí¥Ü¡A§l¤Þ¥Á¶¡¸ê¥»ªº¬ü°ê¤½¦@§ë¸ê¡A¹ï©ó«P¶iªø´Á¥i«ùÄò¥B¥]®eªº¼Wªø¦ÜÃö­«­n¡A¦ýĵ§iºÙ¡A¤¤°ê¤j³W¼Ò°ê®a¤u·~¸É¶Kªº¼Ò¦¡¡A¬O¥@¬É©Ò¤£¯à±µ¨üªº¡C­C­ÛºÙ¡A¬F©²¹ï¾Ô²¤©Ê²£·~ªº¹L«×¸É¶K¡A¾É­P»s³y·~²£¯à¹L³Ñ¡A²£¯à»·»·¶W¹L¯h³nªº°ê¤º»Ý¨D¡C³oºØ¹L«×§ë¸ê³y¦¨ªº¥X¤fªxÀÝ¡A²{¦b«Â¯ÙþÓ¥þ²yªº´N·~¡A¨Ã¾É­P¬ü°ê©M¨ä¥L¦a¤è¥X²{·sªº¶T©ö¾ÀÂS¡C
    • µo§ï©e¤½¥¬¡A®Ú¾Úªñ´Á°ê»Ú¥«³õªo»ùÅܤƱ¡ªp¡A«ö·Ó²{¦æ¦¨«~ªo»ù®æ§Î¦¨¾÷¨î¡A¦Û©ú¤é­â±á¹s®É°_¡A°ê¤º¨T¡B®ãªo»ù®æ¨C¾·¤À§O­°§C190¤¸¤H¥Á¹ô¤Î180¤¸¡C
    • ¡m·s®ö¬ì§Þ¡n¤Þ­z®ø®§³ø¹D¡A¿ÂÃƶ°¹ÎºX¤U¬ì§Þ°Ó·~¤ÆªO¶ô¿ÂÃƼƬì¤w¸g¿W¥ß¹BÀç¡A¨ä¥DÅé¿ÂÃÆÃì(¤W®ü)¼Æ¦r¬ì§Þ¦³­­¤½¥q¤w¸g§¹¦¨20»õ¤¸¤H¥Á¹ô¼W¸ê¡C³ø¹D«ü¡A¿ÂÃƶ°¹Î¸³¨Æªø­ÝCEO¤«½å´É¤µ¦~3¤ëµo¥¬¥þ­û«H¡A«Å¥¬·s¤@½ü²Õ´¬[ºc¤É¯Å¡A¿ÂÃƶ°¹Î¼Æ¦r¬ì§Þ¨Æ·~¸s­ìÁ`µô½±°ê­¸¤wÂ÷¾¡A¥Ñ¶°¹Î¸ê²`°ÆÁ`µô¡B­ì¤j¦w¥þ¨Æ·~¸sÁ`µô»¯»Döt¥X¥ô¿W¥ß«áªº¿ÂÃƼƬìCEO¡C
  • ¥D­nÉ]³õ
    • ¤º¦aªÑ¥«¤U¶^¡A¤WÃÒ«ü¼Æ³Ì¦h¤É2ÂI©Î0.1%¡A°ª¨£3040ÂI¡AÀH«á¥F¤O¦A¤W¡A¤j¥«Âà¶^¡A³Ì¦h¶^14ÂI©Î0.48%¡A§C¨£3022ÂI¡A¥þ¤é¦¬¥«³ø3028ÂI¡A¶^8ÂI©Î0.28%¡A¦¨¥æ3368.71»õ¤¸¤H¥Á¹ô¡C²`¦¨«ü¤ÏÂШ«§C¡A³Ì¦h¤É26ÂI©Î0.29%¡A°ª¨£9296ÂI«á©ÓÀ£¦^³n¡A³Ì¦h¶^79ÂI©Î0.85%¡A§C¨£9190ÂI¡A¥þ¤é¦¬¥«³ø9206ÂI¡A¶^63ÂI©Î0.69%¡A¦¨¥æ4156.03»õ¤¸¡C¨â¥«¦¨¥æ¦X­p¦^¤É¦Ü7525»õ¤¸¡C
    • ¬ü°ê³qµÈ§e­°·Å¸ñ¶H¡A±©ÁpÀx§½©x­û¹w´Á¤µ¦~¥u´î®§¤@¦¸¡A¨È¤Ó°ÏªÑ¥«­Ó§Oµo®i¡C¤é¥»ªÑ¥«³s¶^¨â¤é¡A¤é¸g¥­§¡«ü¼Æ¦¬³ø38720ÂI¡A¶^156ÂI©Î0.4%¡C
    • ¾¨ºÞ¬ü°ê³qµÈ¶i¤@¨B­°·Å¡A±©ªk°ê¬F§½¤£©ú®Ô§Q²H¥«³õ®ðª^¡A¹D«ü§C¶}35ÂI«á¡A¶^´T§YÂX¤j¦Ü304ÂI¡A´¿§C¨£38407ÂI¡F¼Ð«ü¤@«×­Ë¶^0.34%¡A§À¬q½Ä¤W5441ÂI§Y¥«·s°ª¡F¯Ç«ü¦­¬q³Ì¦h¤É0.76%¡A³Ð17741ÂI§Y¥«·s°ª¡C¬ü¥«¦¬¥«¡A¹D«ü¶^´TÁY¦Ü65ÂI©Î0.17%¡A³ø38647ÂI¡F¼Ð«ü¤ÏÂЦ^¤É0.23%¡A³ø5433ÂI¡F¯Ç«üº¦0.34%¡A³ø17667ÂI¡C
  • Àô²yºîµû
    • ¬ü°ê³Ì·s¤½¥¬ªº³qµÈ¼Æ¾Ú¸û¹w´Á·Å©M¡AµLꥫ³õ´¢´úÁpÀx§½¤µ¦~´î®§¦¸¼Æ¥u¦³¤@¦¸ªº¬Ýªk¤É·Å¡A¬ü¤¸¶×»ù©P¥|§e±j¡C¬ü¶×«ü¼Æ¤@«×¤É0.61%¡A¦Ü105.284¡C¬ü°ê10¦~´Á°ê®w¨é´F®§²v¤U·Æ¦Ü4.221Íù¡A¶^´T¬°9.5­Ó°òÂI¡C

    ¬ü°ê³Ì·s¤½¥¬ªº³qµÈ¼Æ¾Ú¸û¹w´Á·Å©M¡AµLꥫ³õ´¢´úÁpÀx§½¤µ¦~´î®§¦¸¼Æ¥u¦³¤@¦¸ªº¬Ýªk¤É·Å¡A¬ü¤¸¶×»ù§e±j¡A°ê»Úª÷»ù©P¥|°¾³n¡C²{³fª÷¤@«×°ª¨£¨C¯s´µ2326¬ü¤¸¡A¨ä«á¥Ñ©ó¬ü°ê¼Æ¾Ú¤í¨Î¦Ó¤U·Æ¡A³Ì¦h¶^1.26%¡A§C¨£2295.68¬ü¤¸¡A¦¬³ø2303.94¬ü¤¸¡A¦^¦R0.91%¡C...... §ó¦h

    ¦ÊÀÙ¯«¦{ (6160.HK)
    ¬ã¨s³ø§i: ¦ÊÀÙ¯«¦{(6160.HK) : ¥Ø¼Ð»ù122.00´ä¤¸¡C¦ÊÀÙ¯«¦{¦¨¥ß©ó 2010 ¦~¡A¬O¥»¤g³Ð·sÃÄ¥X®üÀsÀY¡A»EµJ¤_¸~½Fªº³Ð·s«¬¤À¤l¹v¦V¤Î¸~½F§K¬ÌªvÀøÃĪ«ªº¬ãµo¤Î°Ó·~¤Æ¡A¬O­º®a¹ê²{¬üªÑ+HªÑ+AªÑ¤T¦a¤W¥«ªº³Ð·sÃÄ¥ø·~¡C¤½¥q¹ê¤O¨ô¶V¡A¨ã³Æ¦­´ÁÃĪ«µo²{¡BÁ{§É¬ã¨s¡B³W¼Ò¤Æªº°ª½è¶qÃĪ«¥Í²£¤Î°Ó·~¤Æµ¥¥þ¤è¦ì¤@Åé¤Æ¯à¤O¡C¤½¥qªº¥|­Ó¥D­nªÑªF¥]¬A¦w¶i¡BBaker Brothers Life Sciences, L.P.¤Î¨ä¤@­P¦æ°Ê¤H¡BHHLR Fund, L.P.¤Î¨ä¤@­P¦æ°Ê¤H¡BCapital Research and Management Company ¤Î¨ä¤@­P¦æ°Ê¤H¤À§O«ùªÑ 18.25%¡B11.30%¡B10.89%¡B7.92%¡A¨ä¤¤³Ì¤jªÑªF¦w¶i¡A¬O¥þ²y±Æ¦W«e20 ¦ìªº¥Íª«ÂåÃĤ½¥q¡C¦ÊÀÙ¯«¦{ªººÞ½u«p«×¤Î¦h¼Ë¤Æµ{«×¦ì©~¥þ²yÄvª§«e¦C¡C¥Ø«e³B©óÁ{§É¤Î°Ó·~¤Æ¶¥¬qªºÃĪ«¬ù 50 ­Ó¡A¤w¤W¥«ÃĪ« 16 ­Ó¡]¥]¬A¦Û¬ã²£«~ 3 ­Ó¡^¡A³B©óÁ{§É¢»´Á¶¥¬qªºÃĪ« 3­Ó¡A³B©óÁ{§É¢º´Á¶¥¬qªºÃĪ« 13 ­Ó¡A³B©óÁ{§É¢¹´Á¶¥¬qªºÃĪ« 18 ­Ó¡C¥t¥~¾Ö¦³ 60 §E¶µÁ{§É«e·sÃĶµ¥Ø¡A³o¨ÇÃĪ«Ãþ«¬¯A¤Î¤p¤À¤lÃÄ¡B³æ§Ü¡BÂù§Ü¡BADC µ¥¦hºØÃþ«¬¡A¦h´ÚÃĪ«¨ã³Æ®t²§¤Æ¤D¦Ü¡§first-in-class¡¨¼ç¤O¡CÂ×´I¡B¦h¤¸¤Æªº¬ãµoºÞ½u¼sªxÂл\¤F¥þ²y 80%ªºÀù¯gÃþ«¬¡]«öµo¯f²v­pºâ¡^¡C¦b¦Û¬ã¤è­±¡A¦ÊÀÙ¾Ö¦³¨ô¶Vªº¤º³¡¶}µo¯à¤O¡A¾Ö¦³¶W 900 ¤HªºÁ{§É«e¬ã¨s¹Î¶¤¡A¦Û¥D¬ãµo²£«~¤¤¥Ø«e¦@¦³ 11 ´Ú²£«~¶i¤J¨ì°Ó·~¤Æ¶¥¬q¤ÎÁ{§É¹êÅ綥¬q¡A¨ä¤¤¦³ 3 ´Ú¤w¸gÀò§å¤W¥«¡A¤À§O¬°¿A¥¬´À¥§½¦Ån¡B´À¹p§Q¯]³æ§Üª`®g²G¡B©¬¦Ì©¬§Q½¦Ån¡A¥t¥~ 8 ´Ú²£«~³B©óÁ{§É¹êÅ綥¬q¡A¥B¬°®t²§¤Æ³]­pªº³Ð·sÃĪ«¡C¦b¦X§@¤è­±¡A¦ÊÀÙ¯«¦{ License in/out±j¤j¡ABD ¯à¤O³B©ó¥þ²y«e¦C¡A2017 ¦~»P·s°ò¤½¥q¡]²{ÁõÄݤ_¦Ê®É¬ü¬I¶QÄ_¡^¹F¦¨¦X§@¡A2019 ¦~©³»P¦w¶i­q¥ß¦X§@¨óij¡A2021 ¦~ 1 ¤ë»P 12 ¤ë¤À§O»P¿ÕµØ¹F¦¨¦X§@¡A¥ý«á¤Þ¶i13 ´Ú°Ó·~¤Æ²£«~ªº¤¤°êÅv¯q¡A¥]¬A¦w¶iªº¦w¥[ºû¡B­¿§Q§´¡B³Í¬¥´µ¡ABMS ªº·ç½Æ¬ü¡Bºû¹F²ï¡AEUSAPharmaªºÂÄ·ÅÏÈ¡B³Í¿A¦Ê¡A¦Ê¶ø®õªº´¶¨©§Æ¡A¥H¤Î¿ÕµØªº®õµá¼Ö¡BÁÚ¦NÚ¬¡Bºû¥þ¯S¡B­¸¥§§´¡BÃÙ¥i¹Fµ¥³Ð·s²£«~¡C¤½¥q¦bÁ{§É¶}µo¡BÁ{§Éµ¦²¤¡BÁ{§É°õ¦æµ¥¤è­±´I¦³¸gÅç¡A¥Ø«e¦b¥þ²y¾Ö¦³3,500+¥B¤´µM¤£Â_¼Wªøªº°Ó·~¤Æ¹Î¶¤¡A¨ä¤¤¤¤°ê¹Î¶¤3,000+¦W¡AÂл\¶W¹L 1,000 ®aÂå°|¡C¤½¥qªº¬ãµo§G§½¤wÂл\ ADC¡BÂù§Ü/¦h§Ü¡BCDAC¡]PROTAC¡^¡BCAR-NK¡BmRNA µ¥¦b¤ºªº¦hºØ¤j/¤p¤À¤lÃĪ«¥H¤Î·sªºÃĪ«§Î¦¡¡A¹w­p±N¦³±æ±a¨Ó«ùÄòªº³Ð·s²£«~¿é¥X¡C°]°È¼Æ¾ÚÅã¥Ü¡A¤½¥qªñ¤­¦~Àç·~¦¬¤J¡B²£«~Á`¦¬¤J¤Î®Ö¤ß²£«~¦¬¤J«ùÄò«O«ù°ª³t¼Wªø¡A¬ãµo¶O¥Î¤Î¾P°â/ºÞ²z¶O¥Î¼W³t«ùÄò©ñ½w¡A¨ä¸gÀçÁ«·l¦b 2022 ¦~ªï¨Ó­º¦¸´îÁ«¡A¸gÀç©Ê¬Õ§Q©äÂI¦³±æ¨ì¨Ó¡C2023¦~¡A¤½¥q¹ê²{Àç·~¦¬¤J174.2 »õ¤¸¡A¤ñ¤W¦~¦P´Á¼W¥[82.13%¡F¹ê²{²bÁ«·l67.2 »õ¤¸¡A¤ñ¤W¦~¦P´Á´î¤Ö69.3 »õ¤¸¡F³ø§i´Á¤º¡A¸gÀ笡°Ê²£¥Íªº²{ª÷¬y¶q²bÃB¬°-77.9»õ¤¸¡F¥þ¦~¬ãµo§ë¤J¬°128.1 »õ¤¸¡A»P¤W¦~¦P´Á¬Û¤ñ¼Wªø14.90%¡C2024¦~¤@©u«×¡A¤½¥q¹ê²{Àç·~¦¬¤J53.59»õ¤¸¡A¦P¤ñ¼Wªø74.8%¡F¹ê²{ÂkÄݤ_¤W¥«¤½¥qªÑªFªº²b§Q¼í-19.08»õ¤¸¡A¤W¦~¦P´Á¬°-26.13»õ¤¸¡AÁ«·l¦P¤ñÁY¤p¡C¦ÊÀÙ²£«~²Õ¦X¤´³B©ó°ª³t¼WªøºA¶Õ¡A¦b²£«~¦¬¤J«O«ù°ª¼W³tªº±¡ªp¤U¡A¤½¥qªº¥«­È¤ô¥­±N«ùÄò´£¤É¡C


    ¥«ªp¤ÀªR¡G¬ü°ê³qµÈ§e­°·Å¸ñ¶H¡A±©ÁpÀx§½©x­û¹w´Á¤µ¦~¥u´î®§¤@¦¸¡A¨È¤Ó°ÏªÑ¥«­Ó§Oµo®i¡C¤é¥»ªÑ¥«³s¶^¨â¤é¡A¤é¸g¥­§¡«ü¼Æ¦¬³ø38720ÂI¡A¶^156ÂI©Î0.4%¡C......§ó¦h

    ¥»¦a«ü¼Æ
           ÂI¼Æ    ¤É¶^   ¤É¶^%

    Àô²y«ü¼Æ
           ÂI¼Æ    ¤É¶^   ¤É¶^%

    A-H·¸»ù(§éÅý) ªí
    ¥N¸¹ ¤½¥q¦WºÙ H ªÑ
    ¦¬¥«»ù
    A ªÑ
    ¦¬¥«»ù
    A - H
    ·¸»ù

    ¨ä¥L
       ÂI¼Æ     ¤É¶^   ¤É¶^%
      
      


    ®ü¥~¬ã¨s³ø§i


    §ë¸êªA°È¤¤¤ß


    ¬d¸ß¼ö½u¡G2277 6666 ©Î investornotes@phillip.com.hk
    ¦pªG­¶­±Åã¥Ü¤£¥¿±`½ÐÂIÀ» ¦¹³B¬d¬Ý³sµ²©ó¸Uºûºô¤Wªºª©¥»¡C
     

    ¥»¤å©Ò¥]§tªº¸ê®Æ§¡¬°½÷¥ßµý¨é(­»´ä)¦³­­¤½¥q©Î¨äªþÄݤ½¥q (¡u¶°¹Î¡v) ±q¬Û«H¬°·Ç½Tªº¨Ó·½·j¶°¡A¦ý¹ï¥ô¦ó¦]«H¿à©Î°Ñ¦Ò¦³Ãö¤º®e©Ò¾É­Pªº·l¥¢¡A·§¤£­t³d¡C¥»¶°¹Î (©Î¨ä¹µ­û) ¥i¯à«ù¦³¥»¤å©Ò­z¦³Ãöªº§ë¸ê²£«~¡C¦UÃþ²£«~ªº­·ÀI¡A½Ð°Ñ¾\¥»¤½¥qºô­¶ http://www.phillip.com.hk¡m­·ÀI©ÜÅSÁn©ú¡n¡C

    ¦p±z¤£·Q¦A¦¬¨ú¹q¤l±À¼s¶l¥ó¡A½Ð«ö¦¹³B¡C

    ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

    Copyright(C) 2024 Phillip Securities (HK) Ltd. All Rights Reserved.